NCT05211323 2026-03-19
A Study to Determine Whether Chemotherapy and Atezolizumab is Better Than Chemotherapy, Bevacizumab and Atezolizumab in Patients With Advanced Liver Cancer
National Cancer Institute (NCI)
Phase 2 Active not recruiting
Clinical Trials
16 trialsNCT06040099 2026-03-19
EMERALD-Y90
AstraZeneca
Phase 2 Active not recruiting
NCT05359861 2026-03-18
Trial of Atezolizumab and Bevacizumab With SRF388 or Placebo in Patients With Hepatocellular Carcinoma
Coherus Oncology, Inc.
Phase 2 Completed
NCT01165346 2026-03-13
CKNO-HEP
Centre Oscar Lambret
Phase 2 Completed
NCT06096779 2026-03-06
Kirros
Genentech, Inc.
Phase 2 Recruiting
NCT07447050 2026-03-03
Riluzole For Preventing Cognitive Dysfunction in Ca Pts Receiving Chemo (REFOCUS): Pilot Trial
University of California, Irvine
Phase 2 Recruiting
NCT05063565 2026-03-02
ROWAN
Boston Scientific Corporation
Phase 2 Active not recruiting
NCT04134559 2026-02-24
Checkpoint Inhibition In Pediatric Hepatocellular Carcinoma
Dana-Farber Cancer Institute
Phase 2 Recruiting
NCT03785210 2026-02-23
Nivolumab (Anti-PD1), Tadalafil and Oral Vancomycin in People With Refractory Primary Hepatocellular Carcinoma or Liver Dominant Metastatic Cancer From Colorectal or Pancreatic Cancers
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated
NCT06261814 2026-02-17
Contrast Enhanced Ultrasound to Evaluate Response to Chemoembolization in Patients With Liver Tumors
Thomas Jefferson University
Phase 2 Recruiting
NCT07223307 2026-02-09
REGULUS: MRI-guided Adaptive SABR for Liver Cancers
Stanford University
Phase 2 Recruiting
NCT03937830 2026-02-05
Combined Treatment of Durvalumab, Bevacizumab, Tremelimumab and Transarterial Chemoembolization (TACE) in Subjects With Hepatocellular Carcinoma or Biliary Tract Carcinoma
National Institutes of Health Clinical Center (CC)
Phase 2 Active not recruiting
NCT06679985 2026-02-05
A Trial of Casdozokitug in Combination With Toripalimab Plus Bevacizumab in Participants With Unresectable and/or Locally Advanced or Metastatic Hepatocellular Carcinoma
Coherus Oncology, Inc.
Phase 2 Recruiting
NCT06855225 2026-01-14
A Phase II Study of Single Tremelimumab With Regular Interval Durvalumab Plus Gemcitabine and Cisplatin in Locally Advanced Unresectable/Metastatic Combined Hepatocellular-cholangiocarcinoma
Hoosier Cancer Research Network
Phase 2 Not yet recruiting
NCT07312292 2025-12-31
RADIANT
UMC Utrecht
Phase 2 Not yet recruiting
NCT05532319 2025-12-30
FRONT-1
Guangxi Medical University
Phase 2 Completed